Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Avak Kahvejian
AddedFeb 13, 2024
UpdatedMay 31, 2026
Avak Kahvejian

Avak Kahvejian

Founder, Ampersand Biomedicines

CrunchbaseLinkedInThe Org

Avak Kahvejian's Career

Ampersand Biomedicines
Ampersand Biomedicines

Boston, MA, US

Founder
ProFound Therapeutics
ProFound Therapeutics

Cambridge, MA, US

Founder
Cygnal Therapeutics
Cygnal Therapeutics

Cambridge, MA, US

Co-Founder
Laronde
Laronde

Cambridge, MA, US

Board Member· Board
Ring Therapeutics
Ring Therapeutics

Cambridge, MA, US

Board Member· Board
Cellarity
Cellarity

Somerville, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Avak Kahvejian's Career

Ampersand Biomedicines
Ampersand Biomedicines
Series D$50M302020Boston, MA, US
Founder

Similar to Ampersand Biomedicines

ProFound TherapeuticsProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35
AlltrnaAlltrnaCambridge, MA, USTherapeuticsest. 2018AlltrnaCambridge, MA, US · est. 2018

Altrna: Pioneering tRNA therapeutics, deciphering tRNA biology to treat numerous diseases.

Series B · $159M82
Vesalius TherapeuticsVesalius TherapeuticsCambridge, MA, USDrug Developmentest. 2019Vesalius TherapeuticsCambridge, MA, US · est. 2019

Vesalius Therapeutics: Innovating drug development to combat major human illnesses.

Series A · $75M35
Andson BiotechAndson BiotechAtlanta, GA, USBioanalytics, Sample Prepest. 2021Andson BiotechAtlanta, GA, US · est. 2021

Andson Biotech: Enhancing drug development with advanced chemical measurement tech.

Pre-Seed · $500k4
ProFound Therapeutics
ProFound Therapeutics
Series A$75M352022Cambridge, MA, US
Founder
Cygnal Therapeutics
Cygnal Therapeutics
Series D$65M372016Cambridge, MA, US
Co-Founder

Leadership at Cygnal Therapeutics

Pearl HuangPearl HuangBoard Member
Jordi Mata-FinkJordi Mata-FinkCo-Founder
Theo Melas-KyriaziTheo Melas-KyriaziBoard Member
Michael RosenblattMichael RosenblattBoard Member

Similar to Cygnal Therapeutics

SynerGene TherapeuticsSynerGene TherapeuticsPotomac, MD, USCancer Therapeuticsest. 1998SynerGene TherapeuticsPotomac, MD, US · est. 1998

SynerGene Therapeutics: A biopharmaceutical firm innovating nanotech cancer treatments.

Series A · $10.3M5
Signet TherapeuticsSignet TherapeuticsNewton, MA, USCancer Drugsest. 2020Signet TherapeuticsNewton, MA, US · est. 2020

Signet Therapeutics, a biopharmaceutical startup, innovates targeted cancer drugs using unique disease models.

Seed · $20M30
Exalys TherapeuticsExalys TherapeuticsSan Diego, CA, USDrugs, Therapeuticsest. 2018Exalys TherapeuticsSan Diego, CA, US · est. 2018

Exalys Therapeutics develops novel anti-inflammatory drugs, targeting diseases with limited treatments.

Series A · $15M32
Cytonus TherapeuticsCytonus TherapeuticsCarlsbad, CA, USDrug Deliveryest. 2018Cytonus TherapeuticsCarlsbad, CA, US · est. 2018

Cytonus Therapeutics: Innovating precise, safe, and controlled drug delivery with our unique Cargocyte platform.

Series A · $18.9M13
Laronde
Laronde
Series B$490M302017Cambridge, MA, US
Board Member· Board

Leadership at Laronde

John MendleinJohn MendleinCEO
Sophie de BoerSophie de BoerCo-Founder

Similar to Laronde

AlltrnaAlltrnaCambridge, MA, USTherapeuticsest. 2018AlltrnaCambridge, MA, US · est. 2018

Altrna: Pioneering tRNA therapeutics, deciphering tRNA biology to treat numerous diseases.

Series B · $159M82
Senda BiosciencesSenda BiosciencesCambridge, MA, USMedicinesest. 2017Senda BiosciencesCambridge, MA, US · est. 2017

Senda: Innovatively harnessing molecular interactions for advanced medicine development.

Series C · $309M80
InceptiveInceptivePalo Alto, CA, USMedicines, RNA Designest. 2021InceptivePalo Alto, CA, US · est. 2021

RNA design firm using deep learning and high-throughput experiments to create innovative medicines and biotechnologies.

Series A · $120M29
ReNAgade TherapeuticsReNAgade TherapeuticsCambridge, MA, USRNA Therapeuticsest. 2021ReNAgade TherapeuticsCambridge, MA, US · est. 2021

ReNAgade Therapeutics: Pioneering RNA-based solutions for disease treatment through innovative medication production.

Series A · $300M123
Ring Therapeutics
Ring Therapeutics
Series C$253.5M1322017Cambridge, MA, US
Board Member· Board

Leadership at Ring Therapeutics

Tuyen OngTuyen OngCEO
Noubar AfeyanNoubar AfeyanCo-Founder
Erica WeinsteinErica WeinsteinCo-Founder
B. Lynne ParshallB. Lynne ParshallBoard Member
Torben Straight NissenTorben Straight NissenBoard Member
Cellarity
Cellarity
Series C$294M1652017Somerville, MA, US
Board Member· Board

Leadership at Cellarity

Nick PlugisNick PlugisCo-Founder
Ian EstepanIan EstepanBoard Member
Jim CollinsJim CollinsBoard Member
Fabrice ChouraquiFabrice ChouraquiCEO
Stephen BerensonStephen BerensonBoard Member
Marcello DamianiMarcello DamianiBoard Member

Avak Kahvejian's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Avak Kahvejian

Meredith SadouletMeredith SadouletFounder · ProFound NetworkShalini Nag, Ph.D.Shalini Nag, Ph.D.Founder · EvidaSolveTaylor KatzmanTaylor KatzmanCo-Founder · ProviHarry StylliHarry StylliFounder · Biora TherapeuticsPhilippe FunfrockPhilippe FunfrockFounder · ProteogenixEmmanuel QuevyEmmanuel QuevyCo-Founder · Probius